CytoMed Therapeutics Limited
GDTCHealthcare|Biotechnology|SG
$0.86
-0.02 (-2.39%)
DCF Value
$1.16
Tangible Book / Share
$0.45
Cash / Share
$0.12
Financials
Financial Snapshot
Market Cap
$10.2M
Enterprise Value
$12.0M
Revenue (TTM)
$720.3K
Net Income (TTM)
-$5.3M
Cash & Investments
$1.5M
Net Cash
$1.0M
Free Cash Flow (TTM)
-$6.3M
Operating CF (TTM)
-$5.6M
Debt/Equity
0.09
Cash Runway & Burn Rate
Cash on Hand
$1.5M
Quarterly Burn
$1.4M
Monthly Burn
$464.9K
Est. Runway
~1.0 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $459.2K | $930.8K | $2.5M | $1.6M | $9.0M | $5.0M | $2.1M | $1.5M | |
| Operating Cash Flow | -$640.5K | -$851.3K | -$1.7M | -$1.4M | -$3.5M | -$2.7M | -$3.7M | -$5.6M | |
| Free Cash Flow | -$1.8M | -$1.1M | -$2.3M | -$1.9M | -$3.6M | -$4.1M | -$4.4M | -$6.3M | |
| Capital Expenditure | -$1.2M | -$245.3K | -$583.7K | -$476.0K | -$58.5K | -$1.4M | -$703.1K | -$723.1K | |
| Financing Cash Flow | $1.2M | $1.9M | $4.2M | $968.4K | $10.9M | -$64.9K | $208.6K | $1.5M |
R&D Spending
R&D (TTM)
$1.1M
R&D Intensity
149.3%
R&D Growth vs Prior
-51.5%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $69.5K | $324.4K | $720.3K | |
| R&D Expense | $439.8K | $1.0M | $1.1M | $1.5M | $0.00 | $1.9M | $2.2M | $1.1M | |
| R&D % of Revenue | — | — | — | — | — | 2747.5% | 683.6% | 149.3% | |
| SG&A | $40.3K | $154.9K | $588.5K | $705.3K | $0.00 | $1.6M | $2.6M | $486.8K |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $69.5K | $324.4K | $720.3K | |
| Cost of Revenue | $0.00 | $4.6K | $3.5K | $0.00 | $4.4M | $17.1K | $68.0K | $4.9M | |
| Gross Profit | $0.00 | $54.8K | $110.3K | $0.00 | -$4.4M | $52.4K | $256.4K | -$4.2M | |
| R&D | $439.8K | $1.0M | $1.1M | $1.5M | $0.00 | $1.9M | $2.2M | $1.1M | |
| SG&A | $40.3K | $154.9K | $588.5K | $705.3K | $0.00 | $1.6M | $2.6M | $486.8K | |
| Operating Income | -$651.9K | -$1.3M | -$1.2M | -$2.3M | -$4.4M | -$3.6M | -$4.8M | -$5.7M | |
| Interest Expense | $0.00 | $105.5K | $118.4K | $125.2K | $51.3K | $20.3K | $20.9K | $15.6K | |
| Pretax Income | -$858.7K | -$1.9M | -$2.1M | -$3.1M | -$4.1M | -$2.5M | -$4.0M | -$5.3M | |
| Net Income | -$858.7K | -$1.9M | -$2.1M | -$3.1M | -$4.1M | -$2.5M | -$4.0M | -$5.3M | |
| EPS (Diluted) | -0.15 | -0.33 | -0.30 | -0.40 | -0.39 | -0.22 | -0.34 | -0.44 | |
| EBITDA | -$429.1K | -$1.0M | -$1.6M | -$2.6M | -$3.7M | -$2.2M | -$3.6M | -$4.8M | |
| Shares Out. (M) | 5.55 | 5.90 | 6.93 | 7.92 | 10.63 | 11.54 | 11.65 | 11.88 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $374.4K | $887.2K | $2.5M | $1.6M | $9.0M | $5.0M | $2.1M | $1.5M | |
| Short-Term Investments | $84.8K | $43.6K | $15.3K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $549.0K | $1.5M | $3.3M | $2.5M | $10.1M | $6.0M | $3.7M | $3.2M | |
| Total Assets | $2.9M | $3.8M | $6.1M | $5.3M | $12.4M | $10.1M | $8.0M | $7.0M | |
| Total Current Liabilities | $376.6K | $2.7M | $2.9M | $4.2M | $718.9K | $606.5K | $709.2K | $1.2M | |
| Long-Term Debt | $603.4K | $592.0K | $540.4K | $471.0K | $408.9K | $394.2K | $368.7K | $348.3K | |
| Total Liabilities | $1.0M | $3.3M | $3.5M | $4.7M | $1.1M | $1.0M | $1.1M | $1.6M | |
| Stockholders' Equity | $1.9M | $477.0K | $2.6M | $589.7K | $11.3M | $9.0M | $6.5M | $5.0M | |
| Retained Earnings | -$1.1M | -$3.0M | -$5.1M | -$8.2M | -$12.4M | -$14.8M | -$18.8M | -$20.6M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$640.5K | -$851.3K | -$1.7M | -$1.4M | -$3.5M | -$2.7M | -$3.7M | -$5.6M | |
| Capital Expenditure | -$1.2M | -$245.3K | -$583.7K | -$476.0K | -$58.5K | -$1.4M | -$703.1K | -$723.1K | |
| Free Cash Flow | -$1.8M | -$1.1M | -$2.3M | -$1.9M | -$3.6M | -$4.1M | -$4.4M | -$6.3M | |
| Investing Cash Flow | -$1.2M | -$492.3K | -$825.6K | -$475.5K | -$2.7M | $1.1M | $929.3K | $1.7M | |
| Financing Cash Flow | $1.2M | $1.9M | $4.2M | $968.4K | $10.9M | -$64.9K | $208.6K | $1.5M | |
| Issuance of Stock | $0.00 | $479.8K | $4.0M | $0.00 | $0.00 | $0.00 | $283.1K | $287.4K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$29.8K | -$11.0K | -$59.0K | -$79.1K | -$40.5K | -$44.6K | -$53.5K | -$41.5K | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $694.2K | $130.4K | |
| Net Change in Cash | $374.4K | $886.6K | $1.6M | -$942.1K | $4.6M | -$1.5M | -$2.6M | -$1.4M |
Dilution Tracker
Shares outstanding grew 97.5% over 5 years — significant dilution
Shares Outstanding
12M
5-Year Share Growth
+97.5%
Stock Issuance (TTM)
$287.4K
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 5.55 | 5.90 | 6.93 | 7.92 | 10.63 | 11.54 | 11.65 | 11.88 | |
| Change vs Prior % | — | 6.2% | 17.6% | 14.1% | 34.3% | 8.6% | 0.9% | 2.0% | |
| Stock Issuance | $0.00 | $479.8K | $4.0M | $0.00 | $0.00 | $0.00 | $283.1K | $287.4K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $694.2K | $130.4K |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | — | 75.4% | 79.0% | -577.7% | |
| Operating Margin % | — | — | — | — | — | -5175.3% | -1476.3% | -794.6% | |
| Net Margin % | — | — | — | — | — | -3621.1% | -1227.1% | -730.3% | |
| EBITDA Margin % | — | — | — | — | — | -3116.8% | -1101.7% | -671.3% | |
| FCF Margin % | — | — | — | — | — | -5912.5% | -1356.6% | -874.9% | |
| ROE % | -44.4% | -407.1% | -79.8% | -531.0% | -36.7% | -28.1% | -60.8% | -91.4% | |
| ROA % | -29.2% | -50.8% | -34.0% | -59.6% | -33.3% | -25.0% | -49.8% | -75.1% | |
| ROIC % | -25.0% | -38.3% | -19.7% | -48.5% | -37.2% | -37.8% | -65.3% | -97.9% | |
| R&D / Revenue % | — | — | — | — | — | 2747.5% | 683.6% | 149.3% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 366.7% | |
| Gross Profit | 0.0% | 0.0% | 101.1% | -100.0% | 0.0% | 101.2% | 389.5% | |
| Operating Income | 0.0% | -103.7% | 12.9% | -102.4% | -86.4% | 17.5% | -33.1% | |
| Net Income | 0.0% | -126.2% | -6.8% | -51.0% | -32.0% | 39.1% | -58.2% | |
| EPS (Diluted) | 0.0% | -120.0% | 9.1% | -33.3% | 2.5% | 43.6% | -54.5% | |
| Operating Cash Flow | 0.0% | -32.9% | -101.7% | 18.2% | -152.0% | 23.5% | -36.5% | |
| Free Cash Flow | 0.0% | 39.9% | -109.8% | 18.2% | -91.4% | -14.2% | -7.1% | |
| R&D Expense | 0.0% | 136.0% | 5.0% | 39.7% | -100.0% | 0.0% | 16.1% | |
| SG&A Expense | 0.0% | 283.8% | 280.0% | 19.9% | -100.0% | 0.0% | 60.8% | |
| Total Assets | 0.0% | 29.9% | 59.4% | -13.9% | 136.2% | -18.8% | -20.7% | |
| Book Value / Share | 0.0% | -76.8% | 363.3% | -80.1% | 1325.2% | -26.1% | -24.9% | |
| Debt | 0.0% | 342.8% | 9.3% | 29.8% | -89.4% | 3.1% | 4.2% | |
| Diluted Shares | 0.0% | 6.2% | 17.6% | 14.1% | 34.3% | 8.6% | 0.9% |
Valuation
P/E (TTM)At Loss
P/S18.09
P/B2.63
10Y Low / Med / High3.07 / 14.40 / 72.00
EV/EBITDAAt Loss
EV/Revenue16.69
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.16
Tangible Book / Share
$0.45
Net Current Assets / Share
$0.14
Graham Net-Net
$0.01
Cash / Share
$0.12
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -35.89 | -16.02 | -17.98 | -13.41 | -16.57 | -21.10 | -5.07 | -2.51 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 770.82 | 61.86 | 18.09 | |
| P/B Ratio | 15.44 | 65.35 | 14.40 | 72.00 | 6.09 | 5.98 | 3.07 | 2.63 | |
| EV/EBITDA | -70.36 | -32.14 | -24.45 | -17.27 | -16.25 | -22.65 | -5.16 | -2.49 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 705.98 | 56.89 | 16.69 |
Analyst Estimates & Quality
Altman Z-Score
-1.42
Distress
Piotroski F-Score
3
Weak